Propenoate derivatives of betulin
AssigneeGlaxoSmithKline LLC
InventorsNianhe Han, Brian Alvin Johns, Jun Tang
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are as described herein. Compounds of the present invention are useful for the treatment of HIV.
Claims29
A compound comprising the structure of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- W is selected from —CH2— or —C(═O)—;
- X is selected from the group consisting of H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, NH2, —CN, —C(O)R6, -(Q)nR3, —(C1-C6)alkyl-N(R3)2, —(C1-C6)alkyl-OR3—(C1-C6)alkoxy, and amino-(C1-C6)alkyl;
- Y is selected from —NR1R2 or —OR5;
- Z is
- R1 is selected from the group consisting of H, (C1-C12)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, —(C1-C6)alkyl-N(R3)2, —(C1-C6)alkyl-OR3;
- R2 is selected from the group consisting of H, (C1-C12)alkyl, (C2-C12)alkenyl, (C2-C12) alkynyl, and -(Q)nR3;
- R1 and R2 can optionally join together along with the nitrogen to which they are joined to form a 4 to 12 membered heterocyclyl or heteroaryl ring, each independently containing one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, or —SO2—, and wherein said heterocyclyl or heteroaryl ring may be also optionally and independently substituted with one to three R10 groups;
- R3 is independently selected from the group consisting of H, (C1-C-6)alkyl, —R4,
- wherein:
- A is (C5-C14)aryl,
- B is selected from (C2-C9)heterocycle or (C2-C9)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
- C is (C3-C8)cycloalkyl;
- R4 is independently selected from the group consisting of halo, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl;
- —CF3, —OCF3, —N(R5)2, —(CH2)r-heterocycle, —C(O)OH, —C(O)NH2, and —NO2;
- R5 is selected from the group consisting of H, (C1-C6)alkyl, and (C3-C-8)cycloalkyl;
- R6 is independently H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —OCF3, —NR7R8, heterocycle, —(CH2)rNR7R8, —C(O)OH, —C(O)NH2, wherein two R6 groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, wherein the cycloalkyl ring may be optionally substituted by one to three R10 groups;
- R7 and R8 are independently selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, -Q-aryl-(R4)n, —NR14R15, —C(O)CH3, wherein R7 and R8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, or —SO2—, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R10 groups;
- R9, R10, and R11 are independently selected from the group consisting of oxo, halo, (C1-C6)alkoxy, —R3(R6)q, —OR3(R6)q, nitro, —NR14R15, —SO2R3, (C1-C6)alkyl, —C(O)R7, —R1YR3, and —CO(O)R2, wherein any two R9, R10 or R11 groups can optionally join to form a 3 to 8 membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, or —SO2—, and wherein the cycloalkyl, aryl, heterocyclyl or heteroaryl ring may be optionally substituted by one to three R4 groups;
- R12 and R13 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r, —O[C(R6)2]r—, oxo, halo, —C(O)R7, —NR1R2, and —CO(O)R2, wherein R12 and R13 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, —SO2—, wherein the cycloalkyl ring or heterocyclyl ring may be optionally substituted by one to three R10 groups;
- R14 and R15 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —R3(R6)q, and —OR3(R6)q, wherein R14 and R15 may be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring optionally containing one or three heteroatoms from —NR5—, —O—, —S—, —S(O)—, or —SO2—, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R10 groups;
- Q is —[C(R6)2]r—;
- m and n are independently 0, 1, 2, 3, or 4;
- p is independently 0, 1, 2, 3, or 4;
- and
- r and q are independently 0, 1, 2, 3, or 4.
A compound comprising the structure of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- W is selected from —CH2— or —C(═O)—;
- X is selected from H or C1-C6-alkyl;
- Y is selected from —NR1R2 or —OR5;
- Z is
- R1 and R2 are each independently selected from the group consisting of H, —(C1-C6)alkyl-OR3, and -(Q)nR3;
- R3 is selected from the group consisting of
- wherein:
- A is (C5-C14)aryl,
- B is selected from (C2-C9)heterocycle or (C2-C9)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
- C is (C3-C7)cycloalkyl;
- R5 is H;
- R6 is independently selected from H or (C1-C6)alkyl, wherein two R6 alkyl groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, wherein the cycloalkyl ring may be optionally substituted by one to three R10 groups;
- R9, R10, and R11 are independently selected from the group consisting of oxo, halo, (C1-C6)alkoxy, —R3(R6)q, —OR3(R6)q, nitro, —NR14R15, —SO2R3, (C1-C6)alkyl, —C(O)R7, —R1YR3, and —CO(O)R2;
- R12 and R13 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, halo, —C(O)R7, —NR1R2, and —CO(O)R2, wherein R12 and R13 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, —SO2—, wherein the cycloalkyl ring or heterocyclyl ring may be optionally substituted by one to three R10 groups;
- R14 and R15 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —R3(R6)q, and —OR3(R6)q, wherein R14 and R15 may be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring optionally containing one or three heteroatoms from —NR5—, —O—, —S—, —S(O)—, or —SO2—, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R10 groups;
- Q is —[C(R6)2]r;
- m and n are independently 0, 1, 2, 3, or 4;
- p is independently 0, 1, 2, 3, or 4;
- and
- r and q are independently 0, 1, 2, 3, or 4.
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
A compound or a pharmaceutically acceptable salt thereof having the structure:
Dependencies are inferred from the claim text.